Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study.

Yuta Sano, Masaharu Inoue, Satoshi Washino, Suguru Shirotake, Hideki Takeshita, Yuji Miura, Akinari Nakayama, Shoichi Nagamoto, Tomoaki Miyagawa, Masafumi Oyama, Satoru Kawakami, Kazutaka Saito, Yoh Matsuoka